Acetaminophen to Prevent Ischemic Oxidative Reperfusion Injury During Percutaneous Coronary Intervention for Acute Myocardial Infarction (APRIORI Pilot)
Status
Withdrawn
Conditions
Acute Myocardial Infarction
Treatments
Drug: Acetaminophen
Drug: Placebo
Details and patient eligibility
About
The purpose of this study is to test the hypothesis that acetaminophen will reduce lipid peroxidation and isoprostane formation during reperfusion after percutaneous revascularization for acute myocardial infarction.
Sex
All
Ages
18+ years old
Volunteers
No Healthy Volunteers
Inclusion criteria
- Patients presenting with STEMI
Exclusion criteria
- Duration of symptoms > 12 hours
- Suspected LM or proximal LAD occlusion (based on EKG interpretation)
- Hemodynamic instability
- Acetaminophen use in prior 24 hours
- Use of dipyridamole, or Aggrenox, a formulation of aspirin and extended-release dipyridamole, within 48 hours
- Current use of the following medications: phenytoin, valproic acid, phenobarbital, topiramate, rifampin, carbamazepine, cyclophosphamide, ritonavir, efavirenz, St. John's Wort
- Chronic heavy alcohol use
- Chronic liver disease (other than non-alcoholic fatty liver infiltration)
- Severe valvular heart disease
- Stroke in the past 60 days
- Active major bleeding
- Major surgery in the past 30 days
- Ongoing treatment for active malignancy
- Life expectancy less than 12 months as determined by the patient's attending physician
- Pregnancy
- asthma or severe COPD
- active wheezing on presentation
- allergy or prior adverse reaction to adenosine
Trial design
Primary purpose
Treatment
Allocation
Randomized
Interventional model
Single Group Assignment
Masking
Triple Blind
0 participants in 2 patient groups, including a placebo group
Acetaminophen
Active Comparator group
Treatment:
Drug: Acetaminophen
Placebo
Placebo Comparator group
Treatment:
Drug: Placebo
Trial contacts and locations
1
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems